Oral administration of resveratrol is able to amelioration the progression of diabetic nephropathy, but the underlying cause is unknown. In this report, we demonstrated that resveratrol relieved a series of indicators of diabetic nephropathy. Oral administration of resveratrol was able to sequester negatively charged bacterial endotoxin in the gut, leading to 1) reduced plasma endotoxin levels, 2) resolved systemic inflammation and the Intestinal environment, and 3) lowered renal inflammation and improved renal function. Gut dysbiosis, characterized as an increment of Bacteroides, Alistipes, Turicibacter and Parabacteroides, and reduction of Enterococcus , was fully modulated by resveratrol, indicating that inflammatory-associated microbiome in the gut are critical for the metabolic endotoxemia. Furthermore, fecal bacteria transplant, derived from heathy resveratrol-treated mices, was sufficient to antagonize the renal dsyfunction and rebalance of gut microbiome in the recipient mice. These results indicate that resveratrol mediated changes in the gut microbiome may play an important role in the mechanism of action of resveratrol, which provide supporting evidence for the gut-kidney axis in DN.
D. Dafa: None. L. Yibing: None. C. Tingting: None. Y. Xiaolong: None. M. Jianhua: None.
Major Research and Development Project of Jiangsu (BE2016800); Nanjing Science and Technology Plan Project (BE201715015)